Literature DB >> 34503975

Characterization of VU0468554, a New Selective Inhibitor of Cardiac G Protein-Gated Inwardly Rectifying K+ Channels.

Allison Anderson1, Baovi N Vo1, Ezequiel Marron Fernandez de Velasco1, Corey R Hopkins1, C David Weaver1, Kevin Wickman2.   

Abstract

G protein-gated inwardly rectifying K+ (GIRK) channels are critical mediators of excitability in the heart and brain. Enhanced GIRK-channel activity has been implicated in the pathogenesis of supraventricular arrhythmias, including atrial fibrillation. The lack of selective pharmacological tools has impeded efforts to investigate the therapeutic potential of cardiac GIRK-channel interventions in arrhythmias. Here, we characterize a recently identified GIRK-channel inhibitor, VU0468554. Using whole-cell electrophysiological approaches and primary cultures of sinoatrial nodal cells and hippocampal neurons, we show that VU0468554 more effectively inhibits the cardiac GIRK channel than the neuronal GIRK channel. Concentration-response experiments suggest that VU0468554 inhibits Gβγ-activated GIRK channels in noncompetitive and potentially uncompetitive fashion. In contrast, VU0468554 competitively inhibits GIRK-channel activation by ML297, a GIRK-channel activator containing the same chemical scaffold as VU0468554. In the isolated heart model, VU0468554 partially reversed carbachol-induced bradycardia in hearts from wild-type mice but not Girk4-/- mice. Collectively, these data suggest that VU0468554 represents a promising new pharmacological tool for targeting cardiac GIRK channels with therapeutic implications for relevant cardiac arrhythmias. SIGNIFICANCE STATEMENT: Although cardiac GIRK-channel inhibition shows promise for the treatment of supraventricular arrhythmias, the absence of subtype-selective channel inhibitors has hindered exploration into this therapeutic strategy. This study utilizes whole-cell patch-clamp electrophysiology to characterize the new GIRK-channel inhibitor VU0468554 in human embryonic kidney 293T cells and primary cultures. We report that VU0468554 exhibits a favorable pharmacodynamic profile for cardiac over neuronal GIRK channels and partially reverses GIRK-mediated bradycardia in the isolated mouse heart model.
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34503975      PMCID: PMC8626782          DOI: 10.1124/molpharm.121.000311

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  55 in total

1.  The beta gamma subunits of GTP-binding proteins activate the muscarinic K+ channel in heart.

Authors:  D E Logothetis; Y Kurachi; J Galper; E J Neer; D E Clapham
Journal:  Nature       Date:  1987 Jan 22-28       Impact factor: 49.962

2.  Number and stoichiometry of subunits in the native atrial G-protein-gated K+ channel, IKACh.

Authors:  S Corey; G Krapivinsky; L Krapivinsky; D E Clapham
Journal:  J Biol Chem       Date:  1998-02-27       Impact factor: 5.157

3.  Evaluation of the role of I(KACh) in atrial fibrillation using a mouse knockout model.

Authors:  P Kovoor; K Wickman; C T Maguire; W Pu; J Gehrmann; C I Berul; D E Clapham
Journal:  J Am Coll Cardiol       Date:  2001-06-15       Impact factor: 24.094

4.  Discovery of 'molecular switches' within a GIRK activator scaffold that afford selective GIRK inhibitors.

Authors:  Wandong Wen; Wenjun Wu; Ian M Romaine; Kristian Kaufmann; Yu Du; Gary A Sulikowski; C David Weaver; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2013-06-20       Impact factor: 2.823

5.  Identification of a Kir3.4 mutation in congenital long QT syndrome.

Authors:  Yanzong Yang; Yiqing Yang; Bo Liang; Jinqiu Liu; Jun Li; Morten Grunnet; Søren-Peter Olesen; Hanne B Rasmussen; Patrick T Ellinor; Lianjun Gao; Xiaoping Lin; Li Li; Lei Wang; Junjie Xiao; Yi Liu; Ying Liu; Shulong Zhang; Dandan Liang; Luying Peng; Thomas Jespersen; Yi-Han Chen
Journal:  Am J Hum Genet       Date:  2010-06-11       Impact factor: 11.025

6.  Galphai3 primes the G protein-activated K+ channels for activation by coexpressed Gbetagamma in intact Xenopus oocytes.

Authors:  Moran Rubinstein; Sagit Peleg; Shai Berlin; Dovrat Brass; Nathan Dascal
Journal:  J Physiol       Date:  2007-02-08       Impact factor: 5.182

7.  Mechanisms underlying the activation of G-protein-gated inwardly rectifying K+ (GIRK) channels by the novel anxiolytic drug, ML297.

Authors:  Nicole Wydeven; Ezequiel Marron Fernandez de Velasco; Yu Du; Michael A Benneyworth; Matthew C Hearing; Rachel A Fischer; Mark John Thomas; C David Weaver; Kevin Wickman
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-07       Impact factor: 11.205

8.  G-protein-coupled inward rectifier potassium current contributes to ventricular repolarization.

Authors:  Bo Liang; Jakob D Nissen; Morten Laursen; Xiaodong Wang; Lasse Skibsbye; Matthew C Hearing; Martin N Andersen; Hanne B Rasmussen; Kevin Wickman; Morten Grunnet; Søren-Peter Olesen; Thomas Jespersen
Journal:  Cardiovasc Res       Date:  2013-10-22       Impact factor: 10.787

9.  Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated IKado.

Authors:  Victor P Long; Ingrid M Bonilla; Stephen Baine; Patric Glynn; Sanjay Kumar; Karsten Schober; Kent Mowrey; Raul Weiss; Nam Y Lee; Peter J Mohler; Sandor Györke; Thomas J Hund; Vadim V Fedorov; Cynthia A Carnes
Journal:  Life Sci       Date:  2019-11-18       Impact factor: 5.037

10.  A benzopyran with antiarrhythmic activity is an inhibitor of Kir3.1-containing potassium channels.

Authors:  Meng Cui; Yaser Alhamshari; Lucas Cantwell; Said Ei-Haou; Giasemi C Eptaminitaki; Mengmeng Chang; Obada Abou-Assali; Haozhou Tan; Keman Xu; Meghan Masotti; Leigh D Plant; Ganesh A Thakur; Sami F Noujaim; James Milnes; Diomedes E Logothetis
Journal:  J Biol Chem       Date:  2021-03-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.